Wanebo J E, Malik J M, VandenBerg S R, Wanebo H J, Driesen N, Persing J A
Department of Surgery, Bethesda Naval Hospital, Maryland.
Cancer. 1993 Feb 15;71(4):1247-53. doi: 10.1002/1097-0142(19930215)71:4<1247::aid-cncr2820710413>3.0.co;2-s.
In order to improve management, the files and tissue sections of 28 cases of malignant peripheral nerve sheath tumors (MPNST) diagnosed at the University of Virginia Health Sciences Center between 1960 and 1990 were reviewed.
Clinical data tabulated included age, sex, race, the presence or absence of von Recklinghausen neurofibromatosis type 1 (NF-1), tumor size, tumor location, type of treatment, and status of surgical margins. Pathologic study included assessment of mitotic rate, divergent differentiation, cellular atypia, necrosis, and vascular reaction.
The median disease-free survival time was 11 months, and the median overall survival time was 44 months. Overall survival and disease-free survival were significantly influenced by patient age, tumor location, tumor size, extent of surgery, and quality of margins. Patients with a family history of neurofibromatosis also had better disease-free survival. None of the other clinical variables correlated with survival.
The authors recommended that patients with NF-1 be followed closely for MPNST development. For most cases, treatment should include aggressive surgery with wide surgical margins combined with adjuvant radiation therapy. Chemotherapy may have a role for treatment failures.
为了改善管理,对1960年至1990年间在弗吉尼亚大学健康科学中心诊断的28例恶性外周神经鞘瘤(MPNST)的病历和组织切片进行了回顾。
汇总的临床数据包括年龄、性别、种族、是否存在1型冯雷克林霍增氏神经纤维瘤病(NF-1)、肿瘤大小、肿瘤位置、治疗类型以及手术切缘情况。病理研究包括评估有丝分裂率、异向分化、细胞异型性、坏死和血管反应。
无病生存期的中位数为11个月,总生存期的中位数为44个月。总生存期和无病生存期受患者年龄、肿瘤位置、肿瘤大小、手术范围和切缘质量的显著影响。有神经纤维瘤病家族史的患者无病生存期也较好。其他临床变量均与生存期无相关性。
作者建议对NF-1患者密切随访MPNST的发生情况。对于大多数病例,治疗应包括手术切除范围广的积极手术联合辅助放疗。化疗可能对治疗失败的病例有作用。